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Tissue regeneration and bone augmentation have slowly
become mainstreams of periodontists’ daily practice. Bi-
ologic agents which attempt to promote soft and hard tissue
repair as well as jump-start the healing process, especially
in medically compromised individuals, are an integral part
of clinical periodontics. Tissue engineering using biologic
agents, such as enamel matrix derivative, platelet-derived
growth factor, platelet-rich plasma or platelet-rich fibrin gel,
bone morphogenetic protein, fibroblast growth factor, low
dosage parathyroid hormone–related protein, or combina-
tion therapy, has recently become a focus of research and
constant debate among clinicians, especially periodontists.
These biologic agents have been tested and show promising
results in promoting soft and hard tissue regeneration.
The purpose of this special issue of Clinical Advances in
Periodontics is to target this emerging field by inviting in-
dividuals who have expertise in this area to share their
insights with our readers. All articles contain the most
updated information and show how each biologic agent
should be used in daily practice. Clinical examples of
how each agent can be used in promoting tissue regener-
ation or bone augmentation are illustrated. In deciding
which agent to use, it is important for clinicians to under-
stand the mechanism of each biological modifier and the
evidence that exists, as well as other factors such as cost/
benefit ratio, risk/benefit ratio, and long-term stability.
Readers are encouraged to understand how these agents
work, when to use them, and where they should be used,
either alone or in combination, so they can make informed
decisions in specific clinical situations.
This special issue beginswith an introductionwith several
focused questions such as: ‘‘What biologic agents are avail-
able to help promote periodontal regeneration and bone
augmentation?’’; ‘‘How should clinicians decide which bio-
logic agent(s) to use?’’; and ‘‘What are the approved uses for
each agent?’’. The agents are then linked to their future per-
spectives in the second paper. In the following papers, the
current available agents are introduced with clinical case
illustrations as well as current evidence. The final paper
demonstrates a combination approach using these agents.
By reading this special issue of Clinical Advances in Peri-
odontics, I hope readers gain a clear understanding of why,
how, where, and when these biologic agents should be used
in clinical practice to promote tissue andbone regeneration.n
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